Harvoni

Conditions Treated

Harvoni is primarily used to treat long-term (chronic) hepatitis C, a viral infection that causes inflammation and potential damage to the liver. It is specifically indicated for patients infected with hepatitis C virus genotypes 1, 4, 5, or 6.

Patient Populations

This medication is approved for use in several different groups, including:

• Adults with chronic hepatitis C.
• Children and adolescents aged 3 years and older.

Specific Medical Situations

Healthcare providers may prescribe Harvoni for patients in various stages of liver health, such as:

• Patients without liver scarring (cirrhosis).
• Patients with compensated cirrhosis, where the liver is scarred but still able to perform its basic functions.
• Patients with advanced (decompensated) cirrhosis, where it is typically used in combination with another antiviral medication called ribavirin.
• Patients who have received a liver transplant and are infected with genotype 1 or 4.

The primary goal of treatment is to clear the hepatitis C virus from the blood. When the virus remains undetectable for 12 weeks or more after treatment is finished, it is considered a sustained virologic response, which indicates the infection has been cured.

Mechanism of Action

Harvoni contains two active ingredients, ledipasvir and sofosbuvir, which are classified as direct-acting antivirals. These medications work by targeting specific proteins the hepatitis C virus (HCV) uses to replicate itself within the body.

How the Ingredients Work

• Ledipasvir: This component blocks a protein called NS5A. The virus requires this protein to copy its genetic material and to assemble new virus particles.
• Sofosbuvir: This component is a polymerase inhibitor. It interferes with an enzyme called NS5B RNA polymerase, which the virus uses to build new strands of RNA. By providing a faulty building block, sofosbuvir stops the virus from completing its genetic code.

By attacking the virus at two different stages of its life cycle, Harvoni prevents the hepatitis C virus from making copies of itself. As the treatment progresses, the viral load in the bloodstream decreases. The goal of this treatment is to reduce the virus to undetectable levels, effectively clearing the infection from the body.

Common Side Effects

The most frequently reported side effects of Harvoni are typically mild and may include:

• Tiredness or fatigue
• Headache
• Nausea
• Diarrhea
• Difficulty sleeping (insomnia)
• Cough
• Dizziness
• Muscle aches or weakness

Serious Side Effects

While rare, some serious side effects can occur. Seek medical attention immediately if you experience any of the following:

• Slow heart rate (bradycardia): This is a significant risk for individuals who also take the heart rhythm medication amiodarone. Symptoms may include fainting, chest pain, shortness of breath, or confusion.
• Allergic reactions: Signs of a severe reaction include hives, swelling of the face, lips, or tongue, and difficulty breathing.
• Hepatitis B reactivation: In people who have previously had a hepatitis B infection, the virus may become active again during or after treatment with Harvoni.
• Severe skin reactions: Though very rare, some individuals may experience significant skin rashes or blistering.

Hepatitis B Virus Reactivation

Harvoni has a boxed warning because it can cause the hepatitis B virus (HBV) to become active again in people who have or have had both hepatitis B and hepatitis C. This reactivation can lead to severe liver problems, liver failure, or death. Healthcare providers typically test for HBV infection before starting Harvoni treatment to monitor for this risk.

Serious Slow Heart Rate

Taking Harvoni with amiodarone, a medication used to treat heart rhythm problems, can cause a serious slowing of the heart rate known as symptomatic bradycardia. This risk is higher for individuals also taking beta-blockers or those with underlying heart conditions. Symptoms of a dangerously slow heart rate may include fainting, dizziness, chest pain, or shortness of breath.

Drug Interactions

Certain medications and herbal supplements can make Harvoni less effective by reducing the levels of the drug in the body. These include:

• Rifampin
• St. John's wort
• Certain seizure medications, such as carbamazepine or phenytoin

Harvoni should not be used in combination with other medications that contain sofosbuvir, as this would result in an excessive dose of that active ingredient.

Other Considerations

The safety of Harvoni during pregnancy or while breastfeeding has not been fully established, and the potential risks are not well-documented in these populations. Additionally, while Harvoni can be used in people with kidney issues, those with severe kidney disease or those undergoing dialysis require close monitoring by a healthcare professional due to limited data.

Pregnancy

There are no adequate studies on the use of Harvoni in pregnant women. Animal studies using doses much higher than those recommended for humans did not show evidence of harm to the fetus. However, because animal data do not always predict human outcomes, Harvoni is generally only recommended during pregnancy when the potential benefit justifies the potential risk.

If Harvoni is used in a treatment regimen that includes ribavirin, extreme caution is required. Ribavirin is known to cause significant birth defects and fetal death. It must not be used by pregnant women or by men whose female partners are pregnant.

Breastfeeding

It is not known if the active ingredients in Harvoni, ledipasvir and sofosbuvir, pass into human breast milk. While these substances have been found in the milk of lactating animals, human data are unavailable. Decisions regarding breastfeeding while taking Harvoni should involve a discussion with a healthcare provider to weigh the benefits of breastfeeding against the mother's need for the medication and any potential risks to the infant.

Dosage Forms

Harvoni is provided in the following oral forms:

• Film-coated tablets: These are solid tablets intended to be swallowed whole.
• Oral pellets: These are supplied in packets. This form is intended for patients who have difficulty swallowing tablets and is typically sprinkled on soft food before consumption.

FDA Approval and Indications

Harvoni, a combination of ledipasvir and sofosbuvir, is approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic hepatitis C virus (HCV) genotypes 1, 4, 5, or 6. It is indicated for use in adults and pediatric patients 3 years of age and older. The medication is used for patients without cirrhosis or with compensated cirrhosis, and in combination with ribavirin for those with decompensated cirrhosis. It is also approved for certain patients co-infected with HIV-1 and for liver transplant recipients.

Boxed Warning

The FDA requires a boxed warning for Harvoni due to the risk of hepatitis B virus (HBV) reactivation. In patients infected with both HCV and HBV, starting treatment with direct-acting antivirals like Harvoni may cause the hepatitis B virus to become active again. This reactivation can result in serious liver injury, liver failure, or death. Healthcare providers are required to screen all patients for evidence of current or prior HBV infection before beginning therapy and monitor for flare-ups during and after treatment.

Safety Communications

The FDA has issued safety communications regarding the use of Harvoni with certain other medications. A significant concern involves the risk of serious symptomatic bradycardia (a dangerously slow heart rate) when Harvoni is taken in combination with amiodarone, a drug used to treat heart rhythm disorders. This interaction can be life-threatening and may require medical intervention or the use of a pacemaker. Additionally, the FDA monitors adverse event reports to identify potential new safety signals, such as skin reactions or other systemic issues, as part of its ongoing regulatory oversight.

Factors Influencing Cost

The total price of Harvoni treatment is primarily determined by the duration of the prescription, which typically lasts 8, 12, or 24 weeks. Other factors include:

• Insurance Coverage: Out-of-pocket costs vary widely between different private insurance plans, Medicare, and Medicaid.
• Generic Options: A generic version containing the same active ingredients (ledipasvir and sofosbuvir) is available and may be more affordable than the brand-name product.
• Pharmacy Choice: Prices can differ between retail pharmacies and specialty pharmacies.

Insurance Requirements

Because Harvoni is a high-cost specialty medication, most insurance companies require a process called prior authorization. This means your doctor must submit documentation to your insurance provider to confirm that the medication is medically necessary before the plan will agree to cover the cost.

Financial Assistance Programs

For individuals who are uninsured or whose insurance does not fully cover the cost, there are options to help manage expenses:

• Patient Assistance Programs: The manufacturer may provide the medication at a reduced cost or for free to patients who meet specific income and eligibility requirements.
• Co-pay Cards: Patients with commercial insurance may be eligible for co-pay coupons that lower the amount paid at the pharmacy counter.